Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Adeleye O. Adeshakin"'
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Immunotherapy has emerged as a promising approach to combat immunosuppressive tumor microenvironment (TME) for improved cancer treatment. FDA approval for the clinical use of programmed death receptor 1/programmed death-ligand 1 (PD-1/PD-L1) inhibito
Externí odkaz:
https://doaj.org/article/9b093e038ab14005960c83d76ee030b4
Autor:
Lukman O. Afolabi, Jiacheng Bi, Xuguang Li, Adeleye O. Adeshakin, Funmilayo O. Adeshakin, Haisi Wu, Dehong Yan, Liang Chen, Xiaochun Wan
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Histone deacetylases (HDAC) are frequently overexpressed in tumors, and their inhibition has shown promising anti-tumor effects. However, the synergistic effects of HDAC inhibition with immune cell therapy have not been fully explored. Natural killer
Externí odkaz:
https://doaj.org/article/533ba0fb59ce44d299f581ecb9b254ec
Autor:
Funmilayo O. Adeshakin, Adeleye O. Adeshakin, Lukman O. Afolabi, Dehong Yan, Guizhong Zhang, Xiaochun Wan
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
The attachment of cells to the extracellular matrix (ECM) is the hallmark of structure–function stability and well-being. ECM detachment in localized tumors precedes abnormal dissemination of tumor cells culminating in metastasis. Programmed cell d
Externí odkaz:
https://doaj.org/article/19df2b03e83d43bb955368f15cd82347
Autor:
Oluwamuyiwa A. Ayanshina, Adeleye O. Adeshakin, Lukman O. Afolabi, Funmilayo O. Adeshakin, Ganiyu O. Alli-Balogun, Dehong Yan, Samuel Essien-Baidoo, Xiaochun Wan
Publikováno v:
Journal of Global Health Reports, Vol 4 (2020)
There is a global rise in the emergence of infectious diseases and the enigmatic coronavirus disease 2019 (COVID-19) being the most recent one. It is ravaging the world with little understanding of its etiology and factors affecting its transmission
Externí odkaz:
https://doaj.org/article/c2c97ee90013437e9652fe9a0003a4e0
Autor:
Funmilayo O. Adeshakin, Adeleye O. Adeshakin, Zhao Liu, Jian Cheng, Pengchao Zhang, Dehong Yan, Guizhong Zhang, Xiaochun Wan
Publikováno v:
Life, Vol 12, Iss 1, p 42 (2021)
Metastasis arises owing to tumor cells’ capacity to evade pro-apoptotic signals. Anoikis—the apoptosis of detached cells (from the extracellular matrix (ECM)) is often circumvented by metastatic cells as a result of biochemical and molecular tran
Externí odkaz:
https://doaj.org/article/992c80e12e174a989dde13a373f8c3c4
Autor:
Dehong Yan, Adeleye O. Adeshakin, Meichen Xu, Lukman O. Afolabi, Guizhong Zhang, Youhai H. Chen, Xiaochun Wan
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
Myeloid-derived suppressor cells (MDSCs) play crucial roles in tumorigenesis and their inhibition is critical for successful cancer immunotherapy. MDSCs undergo metabolic reprogramming from glycolysis to fatty acid oxidation (FAO) and oxidative phosp
Externí odkaz:
https://doaj.org/article/fd11d2edd68a4ae0bd38fc62df394282
Autor:
Adeleye O. Adeshakin, Peipei Zhou, Jean-Yves Métais, Phuong Nguyen, Scott Perry, Heather Sheppard, Xiang Sun, Trevor Cunningham, Hao Shi, Jessica Wagner, Jason T. Yustein, Christopher DeRenzo, Giedre Krenciute, Hongbo Chi, Stephen Gottschalk
Publikováno v:
Cancer Research. 83:1778-1778
Chimeric antigen receptor (CAR) T-cell therapy offers promise to improve outcomes for pediatric patients with recurrent/refractory osteosarcoma (OS), a ‘poor-prognosis’ cancer. However, early-phase clinical studies have shown limited activity des
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0a37fa48d0beeb72b37367d5e5441227
https://doi.org/10.1158/1538-7445.am2023-1778
https://doi.org/10.1158/1538-7445.am2023-1778
Autor:
Dehong Yan, Adeleye O. Adeshakin, Funmilayo O. Adeshakin, Pengchao Zhang, Xiaoxu Lu, Xiaochun Wan, Liu Zhao, Guizhong Zhang, Jian Cheng
Publikováno v:
Journal of Cancer
Most cancer mortality results from metastatic tumor cells and not the localized tumor. Overcoming anoikis is one of the most important steps for detached tumor cells to migrate and metastasize. However, the molecular mechanisms remain to be fully dec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ef03c716dd1367f22e17c3d527646d4
https://doi.org/10.7150/jca.58670
https://doi.org/10.7150/jca.58670
Autor:
Wan Liu, Mengqi Zhang, Dehong Yan, Lulu Wang, Xiaochun Wan, Funmilayo O. Adeshakin, Adeleye O. Adeshakin
Publikováno v:
Biochemical and Biophysical Research Communications. 522:604-611
Regardless of the remarkable clinical success of immune checkpoint blockade (ICB) against PD-1/PD-L1 pathway, this approach has encountered drawbacks in most patients due to the activation of tumor immunosuppressive factors such as myeloid-derived su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c7e85d17117ccd9f6d5739f7ea0b888
https://doi.org/10.1016/j.bbrc.2019.11.155
https://doi.org/10.1016/j.bbrc.2019.11.155
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Frontiers in Immunology
Frontiers in Immunology
Immunotherapy has emerged as a promising approach to combat immunosuppressive tumor microenvironment (TME) for improved cancer treatment. FDA approval for the clinical use of programmed death receptor 1/programmed death-ligand 1 (PD-1/PD-L1) inhibito
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::306f1f2fe8b33abdd484ece328c2700c
https://pubmed.ncbi.nlm.nih.gov/35140716
https://pubmed.ncbi.nlm.nih.gov/35140716